These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 23502429)

  • 1. Rituximab is associated with improved survival for aggressive B cell CNS lymphoma.
    Gregory G; Arumugaswamy A; Leung T; Chan KL; Abikhair M; Tam C; Bajel A; Cher L; Grigg A; Ritchie D; Opat S
    Neuro Oncol; 2013 Aug; 15(8):1068-73. PubMed ID: 23502429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.
    El-Galaly TC; Cheah CY; Bendtsen MD; Nowakowski GS; Kansara R; Savage KJ; Connors JM; Sehn LH; Goldschmidt N; Shaulov A; Farooq U; Link BK; Ferreri AJM; Calimeri T; Cecchetti C; Dann EJ; Thompson CA; Inbar T; Maurer MJ; Gade IL; Juul MB; Hansen JW; Holmberg S; Larsen TS; Cordua S; Mikhaeel NG; Hutchings M; Seymour JF; Clausen MR; Smith D; Opat S; Gilbertson M; Thanarajasingam G; Villa D
    Eur J Cancer; 2018 Apr; 93():57-68. PubMed ID: 29477102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma.
    Cheah CY; Herbert KE; O'Rourke K; Kennedy GA; George A; Fedele PL; Gilbertson M; Tan SY; Ritchie DS; Opat SS; Prince HM; Dickinson M; Burbury K; Wolf M; Januszewicz EH; Tam CS; Westerman DA; Carney DA; Harrison SJ; Seymour JF
    Br J Cancer; 2014 Sep; 111(6):1072-9. PubMed ID: 25072255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
    Ferreri AJ; Bruno-Ventre M; Donadoni G; Ponzoni M; Citterio G; Foppoli M; Vignati A; Scarfò L; Sassone M; Govi S; Caligaris-Cappio F
    Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study.
    Holte H; Leppä S; Björkholm M; Fluge O; Jyrkkiö S; Delabie J; Sundström C; Karjalainen-Lindsberg ML; Erlanson M; Kolstad A; Fosså A; Ostenstad B; Löfvenberg E; Nordström M; Janes R; Pedersen LM; Anderson H; Jerkeman M; Eriksson M
    Ann Oncol; 2013 May; 24(5):1385-92. PubMed ID: 23247661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of local recurrence after rituximab-based chemotherapy alone in stage III and IV diffuse large B-cell lymphoma: guiding decisions for consolidative radiation.
    Jegadeesh N; Rajpara R; Esiashvili N; Shi Z; Liu Y; Okwan-Duodu D; Flowers CR; Khan MK
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):107-12. PubMed ID: 25863758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse.
    Villa D; Connors JM; Sehn LH; Gascoyne RD; Savage KJ
    Haematologica; 2011 Jul; 96(7):1002-7. PubMed ID: 21486867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
    Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
    Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
    Papageorgiou SG; Diamantopoulos P; Levidou G; Angelopoulou MK; Economopoulou P; Efthimiou A; Constantinou N; Katsigiannis A; Korkolopoulou P; Pappa V; Economopoulou C; Georgiou G; Dimou M; Tsirigotis P; Kyrtsonis MC; Kotsianidis I; Kalpadakis C; Dimopoulos MA; Beris P; Meletis J; Pangalis GA; Dervenoulas J; Panayiotidis P; Vassilakopoulos TP
    Hematol Oncol; 2013 Mar; 31(1):10-7. PubMed ID: 22610484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.
    del Rio MS; Choquet S; Hoang-Xuan K; Glaisner S; Fourme E; Janvier M; Soussain C
    J Neurooncol; 2011 Nov; 105(2):409-14. PubMed ID: 21656329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance.
    Wight JC; Yue M; Keane C; Johnston A; Linton K; Chin C; Wai SH; Talaulikar D; Gasiorowski R; Cheah CY; Gregory GP; Dickinson M; Minson A; Coombes C; Ku M; Lam S; Hawkes EA
    Br J Haematol; 2019 Oct; 187(2):174-184. PubMed ID: 31236941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma.
    Zhao D; Qian L; Shen J; Liu X; Mei K; Cen J; Wang Y; Li C; Ma Y
    J Cell Mol Med; 2014 Jun; 18(6):1081-6. PubMed ID: 24628986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
    Abramson JS; Hellmann M; Barnes JA; Hammerman P; Toomey C; Takvorian T; Muzikansky A; Hochberg EP
    Cancer; 2010 Sep; 116(18):4283-90. PubMed ID: 20564149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
    Bromberg JEC; Issa S; Bakunina K; Minnema MC; Seute T; Durian M; Cull G; Schouten HC; Stevens WBC; Zijlstra JM; Baars JW; Nijland M; Mason KD; Beeker A; van den Bent MJ; Beijert M; Gonzales M; de Jong D; Doorduijn JK
    Lancet Oncol; 2019 Feb; 20(2):216-228. PubMed ID: 30630772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.
    Wieduwilt MJ; Valles F; Issa S; Behler CM; Hwang J; McDermott M; Treseler P; O'Brien J; Shuman MA; Cha S; Damon LE; Rubenstein JL
    Clin Cancer Res; 2012 Feb; 18(4):1146-55. PubMed ID: 22228634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab.
    Miyazaki K; Yamaguchi M; Suzuki R; Kobayashi Y; Maeshima AM; Niitsu N; Ennishi D; Tamaru JI; Ishizawa K; Kashimura M; Kagami Y; Sunami K; Yamane H; Nishikori M; Kosugi H; Yujiri T; Hyo R; Katayama N; Kinoshita T; Nakamura S
    Ann Oncol; 2011 Jul; 22(7):1601-1607. PubMed ID: 21199885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy.
    Villa D; Connors JM; Shenkier TN; Gascoyne RD; Sehn LH; Savage KJ
    Ann Oncol; 2010 May; 21(5):1046-52. PubMed ID: 19861575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers.
    Jurczak W; Kroll-Balcerzak R; Giebel S; Machaczka M; Giza A; Ogórka T; Fornagiel S; Rybka J; Wróbel T; Kumiega B; Skotnicki AB; Komarnicki M
    Med Oncol; 2015 Apr; 32(4):90. PubMed ID: 25716885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.